The most highly anticipated cardiovascular science of the year awaits you at ESC Congress 2022 – the world’s largest cardiovascular event.
The packed Press Conference programme launches on Thursday 25 August at 12:00 CEST. Join the ESC President and Congress Programme Chair in person or online for a glimpse of what’s to come. Also on Thursday – the first embargoed Hot Line Press Conference, starting at 18:00 CEST.
Friday, Saturday and Sunday each feature three embargoed Hot Line Press Conferences. That’s a total of 10 Hot Line Press Conferences providing the first look at much awaited results from 36 trials. With priority access to the investigators who will take questions from journalists across the globe. Only accredited media can access embargoed press conferences: get accredited now.
Hot line studies will be presented in Barcelona and broadcast online. Tune in here.
Professor Stephan Windecker, Congress Programme Chair, said: “This year’s hot line programme features numerous large scale trials addressing important clinical questions. The results have the potential to improve patient outcomes and quality of life, change clinical practice and influence guidelines. Noteworthy are, among others, the TIME study, which compared morning versus evening use of blood pressure drugs and kicks off Hot Line Session 1; SECURE, which tested a polypill against usual care on outcomes after recent myocardial infarction and PERSPECTIVE, which studied the effects of neprilysin inhibition on cognitive function in patients with heart failure.”
“A major highlight will be DELIVER, which investigated dapagliflozin in heart failure patients with preserved ejection fraction,” continued Professor Windecker. “Following EMPEROR-Preserved, presented at ESC Congress 2021, it is the second large scale clinical trial to examine SGLT2 inhibitors in a patient population with previously limited treatment options. DELIVER will be complemented by two pre-specified pooled analyses, one with EMPEROR-Preserved and another with DAPA-HF, providing deep insights into heart failure management across various phenotypes. Also of note is REVIVED, comparing revascularisation by means of percutaneous coronary intervention and medical treatment in patients with heart failure due to coronary artery disease.”
Professor Windecker also highlighted Hot Line Session 5, which is dedicated to antithrombotic treatment: “The INVICTUS trial compared a non-vitamin K antagonist oral anticoagulant (NOAC) with vitamin K antagonists in patients with atrial fibrillation and rheumatic heart disease, a setting in which NOACs have not been sufficiently tested to date. This is followed by three phase 2 trials – PACIFIC-AMI, PACIFIC-STROKE and AXIOMATIC-SSP – investigating a novel class of anticoagulants called factor XIa inhibitors among patients with myocardial infarction or stroke.”
“There are many more hot lines with ground-breaking trials on imaging for disease prevention, application of artificial intelligence, telemedicine, and much more,” said Professor Windecker. “Get ready for an exceptional hot line programme.”
Four ESC Clinical Practice Guidelines will be published on 26 August at 08:30 CEST, featuring the first ESC recommendations on preventing heart disease caused by cancer treatment, plus advice on cardiovascular management of patients undergoing non-cardiac surgery, prevention of sudden cardiac death, and management of pulmonary hypertension. View the sessions here.
Across four days, innovations in all areas of cardiovascular medicine will be discussed, from basic science to treatment of urgent and chronic conditions, prevention and health promotion. Many sessions will be streamed live from the congress centre and the full programme will be available on demand.
Professor Windecker said: “This year we celebrate 70 years of ESC Congresses with a very exciting edition. ESC Congress is a truly global event where researchers and health professionals from around the world share their novel science and vast clinical experience. Join us for a packed, cutting edge programme.”
Register now here
Our mission: To reduce the burden of cardiovascular disease.